AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19

AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news